Recombinant Drugs to 2020
|出版商||Greystone Research Associates||商品編碼||439381|
|重組醫藥品市場 Recombinant Drugs to 2020|
|出版日期: 2017年02月10日||內容資訊: 英文||
本報告以近幾年，大幅度增加的重組醫藥品為焦點，提供FDA (美國食品藥物管理局) 、EMA (歐洲藥品管理局) 認證的生物製藥與主要的疾病市場區隔中其地位、可能性的相關調查，目前已經過核准的生物製藥，生物製藥的主要市場區隔，構成全球生物製藥市場的藥物類別、治療層級、市場區隔，生物製藥採購、商業化的供應鏈動態，各藥物/類型的收益情形，主要的生物製藥供應商，及主要市場區隔的規模與市場佔有率等相關彙整。
In recent years, the number of recombinant drugs - including engineered biological drugs in development - has increased significantly. The pace of this growth is encouraging suppliers to view competitors in new ways. Cooperation between and among drug developers and drug producers is occurring much earlier in the drug development cycle, allowing participants to improve supply chains and time-to-market. The result is a rapidly growing market sector that is changing disease therapeutics on a global scale. This report examines FDA and EMA-approved biological drugs and their position and potential in a dozen major disease segments - markets with important implications for drug developers, contract and supply chain partners and infrastructure participants. Growth prospects for key biological drug therapeutic segments will vary over the forecast period covered in this analysis, influenced by demographic, socioeconomic and competitive factors.